NeuShen Therapeutics secured more than $80 million in a Series B to advance three clinical-stage brain-health drug programs. The Shanghai-and-Boston biotech is led by a veteran transpacific drug developer, signaling continued capital appetite for CNS assets with clinical progress. In separate company news, a Lancet-adjacent financing beat also highlighted how deals and M&A are returning as biotech financing conditions improve, according to Truist’s survey of sector leaders. The company-level events align with a market narrative of renewed funding activity and lower near-term regulatory overhang. For operators and investors, the NeuShen round reinforces that CNS development remains a focal area for growth capital even amid high execution risk.